< Back

PolyPid to Participate in Three Upcoming Investor Conferences

Nov 4 - Nov 17, 2020

PETAH TIKVA, Israel, Nov. 04, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will present at two investor conferences in November. Details on the presentations can be found below. The company will also participate in one-on-one investor meetings at the AGP Virtual Healthcare Symposium 2020 on Thursday, November 19.

 

H.C. Wainwright 6th Annual Israel Conference

Date:  Thursday, November 12, 2020
Time: 1:30 PM Eastern Time

 

Stifel 2020 Virtual Healthcare Conference

Date:  Tuesday, November 17, 2020
Time: 8:00 AM Eastern Time
Webcast: https://wsw.com/webcast/stifel27/pypd/2115344 

Technology

PolyPid’s PLEX targeted drug delivery platform enables localized, controlled, continuous release of medication over prolonged periods of time for better patient outcomes.

Read More >
D-PLEX100

D-PLEX100

Provides safe and effective local antibiotic protection against SSI (surgical Site Infection) at the needed tissues or organs by administration during surgical procedures.

Read More >
D-PLEX1000

D-PLEX1000

Comprised of antibiotic eluting ß tri-calcium phosphate (ßTCP) granules, designed for bone related infections applications.

Read More >